The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study
Abstract Background Levodopa–carbidopa intestinal gel (LCIG) treatment, a unique drug delivery system for patients with advanced Parkinson’s disease (PD), is covered by health insurance in Japan since September 2016. Various LCIG procedure/device-associated adverse events (AEs) have been reported; h...
Main Authors: | Kanefumi Yamashita, Yukinori Yube, Yukinao Yamazaki, Takehide Fukuchi, Masaki Kato, Tomoyuki Koike, Takeshi Uehara, Yoshiou Ikeda, Satoshi Furune, Hidehiro Murakami, Eiji Kubota, Shinsuke Fujioka, Yoshinori Sato, Xiaoyi Jin, Tomohiko Suzuki, Kazuhiro Furukawa, Yoshio Tsuboi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12883-021-02269-7 |
Similar Items
-
LCIG in treatment of non‐motor symptoms in advanced Parkinson’s disease: Review of literature
by: Walaa A. Kamel, et al.
Published: (2020-09-01) -
Personalized Medicine in Parkinson’s Disease: New Options for Advanced Treatments
by: Takayasu Mishima, et al.
Published: (2021-07-01) -
Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial
by: Rajesh Pahwa, et al.
Published: (2023-01-01) -
Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease
by: Michael J. Soileau, et al.
Published: (2023-01-01) -
The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
by: Pedersen SW, et al.
Published: (2017-01-01)